Repligen to acquire Avitide for $150m.

Repligen, a life sciences company focused on bioprocessing technology leadership, agreed to acquire Avitide, a biopharmaceutical company, for $150m. "The addition of Avitide is a major step forward in building out our Proteins business and in particular our affinity ligand discovery engine. This acquisition builds off the excellent partnership we have already established with Navigo GmbH and really strengthens and expands our ligand discovery and development capabilities. We are excited to have the entire Avitide team join Repligen and look forward to accelerating the commercialization of Avitide’s discovery platform. Together, we anticipate bringing many new products to market over the coming years, directly addressing the growing need for affinity solutions in gene therapy and other emerging modalities," Tony J. Hunt, Repligen President and CEO.